Albert C.
- Country
- Spain
- Department
- Pediatric oncology department
Research Overview
Data & Insights
Has run more than one trial at 0 of 36 partner sites.
Specializations
Pediatric Oncology
This investigator specializes in treating acute myeloid leukemia (AML) in children and adolescents, with particular emphasis on developing innovative therapeutic approaches for patients aged 0-18 years.
- Pediatric AML Treatment Protocols
- Risk-Based Treatment Stratification
- Early Disease Response Assessment
Their expertise extends to managing various AML subtypes in young patients, incorporating targeted therapeutic strategies.
Molecular Therapeutics
The investigator focuses on targeted treatments for specific genetic mutations, particularly FLT3-ITD positive AML and its relationship with NPM1 mutation status in pediatric patients.
- Targeted Therapy Development
- Genetic Mutation Analysis
- Personalized Treatment Approaches
Their work involves evaluating novel therapeutic agents for genetically defined AML subtypes.
Disease Monitoring
Expertise in advanced disease monitoring techniques, particularly minimal residual disease (MRD) assessment using both flow cytometry and PCR methodologies.
- MRD Quantification Methods
- Treatment Response Monitoring
- Prognostic Assessment
The investigator employs sophisticated monitoring techniques to guide treatment decisions and evaluate therapeutic efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.